ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Merck To Pay $321.6 Million Fine For Illegal Marketing Of Vioxx

DOW JONES NEWSWIRES A U.S. district court judge in Boston ordered Merck & Co. (MRK) to pay a $321.6 million criminal fine for its violation of a federal drug law in connection with its marketing of the former painkiller Vioxx. In December, Merck pleaded guilty to violating the Federal Food, Drug, and Cosmetic Act for introducing a misbranded drug into interstate commerce. The company said it previously recorded a $950 million charge in October 2010 in anticipation of the settlement, which resolves a seven-year investigation. Merck withdrew Vioxx from the market in 2004 after it was linked to a higher risk of heart attacks and strokes. "The government recognized Merck's full cooperation with its investigation and by putting this long-standing investigation to rest, we can more fully focus on discovering, developing and providing innovative medicines and vaccines that save and improve lives around the world," Merck said in a statement. In November, Merck had agreed to pay $950 million and plead guilty to a misdemeanor charge of marketing a misbranded drug, to resolve government allegations that the company illegally promoted Vioxx and deceived the government about the drug's safety. The government alleged that Merck promoted Vioxx for treatment of rheumatoid arthritis before that use was approved by regulators. A portion of the $950 million settlement also was to resolve parallel civil allegations that Merck made false and misleading statements about Vioxx's safety, causing government health programs to pay for the drug's use. Merck denied the civil allegations. Shares were off 14 cents to $38.26 in recent trading. The stock is up 1.5% since the start of the year. -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287;

Stock News for Merck (MRK)
10/26/201617:25:04Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)
10/26/201616:43:18Free Writing Prospectus - Filing Under Securities Act Rules 163/433...
10/26/201613:31:00Merck Prices EUR 1.0 Billion Debt Offering
10/26/201608:00:00Merck Highlights Ongoing Commitment to Fighting Infectious Diseases...
10/26/201606:05:47Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)
10/26/201603:03:00Earnings Watch -- WSJ
10/25/201614:02:00Merck Revenue and Profit Rise on Cancer Drugs, Vaccines -- Update
10/25/201613:03:00Stocks Fall on Mixed Earnings Reports
10/25/201612:03:00Stocks Fall on Mixed Earnings Reports
10/25/201610:32:00Stocks Fall on Mixed Earnings Reports
10/25/201610:12:00Stocks Fall on Mixed Earnings Reports
10/25/201609:39:00Stocks Lifted by Upbeat Data, Earnings
10/25/201608:35:00Stocks Lifted by Upbeat Data, Earnings -- 2nd Update
10/25/201608:20:00Merck Profit Rises on Cancer Drugs, Vaccines
10/25/201608:13:00Merck Revenue and Profit Rise on Cancer Drugs, Vaccines
10/25/201606:50:52Current Report Filing (8-k)
10/25/201606:45:00Merck Announces Third-Quarter 2016 Financial Results
10/24/201621:40:00Merck Drug Gets FDA Approval as a First-Line Lung Cancer Treatment
10/24/201620:50:00Merck Drug Gets FDA Approval as a First-Line Lung Cancer Treatment
10/24/201618:04:00FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Metastatic NS...

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations